(CercleFinance.com) – The biopharmaceutical company Innate Pharma displays cash, cash equivalents and financial assets amounting to 121.9 million euros as of September 30, 2023, with an expected horizon during the second half of 2025 ‘.
‘Thanks to our solid cash position, we continue to implement our strategy of developing innovative proprietary and partnership products,’ comments its CEO Mondher Mahjoubi.
Revenue for the first nine months of 2023 amounted to 36.5 million euros (compared to 44.3 million a year earlier), mainly composed of the recognition of payments received under the agreements with AstraZeneca, Sanofi and Takeda.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
